20.500.12556/DiRROS-12623 Sequential treatment with afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer : an observational study Aim: To assess outcomes in patients with EGFR mutation-positive (Del19, L858R) non-small-cell lung cancer receiving sequential afatinib and osimertinib in a real-world clinical setting. Materials & methods: In this retrospective, observational, multicenter study, patients (n = 204) had T790M-positive disease following first-line afatinib and started osimertinib treatment [>/=]10 months prior to data entry. Primary outcome was time on treatment. Results: Overall median time on treatment was 27.6 months (90% CI: 25.9-31.3), 30.3 months (90% CI: 27.6-44.5) in Del19-positive patients and 46.7 months (90% CI: 26.8-not reached) in Asians. The 2-year overall survival was 78.9%. Conclusion: In real-world clinical practice, sequential afatinib and osimertinib facilitates prolonged, chemotherapy-free treatment in patients with T790M acquired resistance, and is a potentially attractive strategy, especially for Del19-positive tumors. lung neoplasms -- therapy non-small-cell lung cancer afatinib osimertinib epidermal growth factor receptor EGFR observational study pljučne novotvorbe -- terapija nedrobnocelični pljučni rak afatinib osimertinib receptor za epidermalni rastni dejavnik EGFR opazovalna raziskava true false true Future Medicine Ltd Angleški jezik Ni določen 2018 Maximilian Hochmair Neznano 2020-11-09 11:24:15 2020-11-09 11:24:15 2022-08-18 03:38:25 0000-00-00 00:00:00 2018 0 Velika Britanija 0 Soavtorji: Alessandro Morabito, Desiree Hao, Cheng-Ta Yang, Ross A Soo, James C-H Yang, Rasim Gucalp, Balazs Halmos, Lara Wang, Amanda Golembesky, Angela Märten & Tanja Cufer; Nasl. z nasl. zaslona; Opis vira z dne 9. 1. 2019; str. 2861-2874 no. 27 Vol. 14 Nov. 2018 0000-00-00 Zaloznikova Objavljeno NiDoloceno 0000-00-00 0000-00-00 0000-00-00 616-006 1744-8301 10.2217/fon-2018-0711 2048432753 521824025 RAZ_Hochmair_Maximilian_J_i2018.pdf RAZ_Hochmair_Maximilian_J_i2018.pdf 1 3F2D8BA9D4F2488B02256DB856ABFA69 e1e69f0441f3a9c72b9a302fe9a1823d98a0e64478cb5e4c555fe94116c9b8ac 88262259-17b6-11ed-b6b8-001a4af901a5 https://dirros.openscience.si/Dokument.php?lang=slv&id=17209 https://www.futuremedicine.com/doi/full/10.2217/fon-2018-0711?url_ver=Z39.88-2003&rfr_id=ori%3Arid%3Acrossref.org&rfr_dat=cr_pub%3Dpubmed# 1 https://dirros.openscience.si/Dokument.php?lang=slv&id=15341 Univerzitetna klinika za pljučne bolezni in alergijo Golnik 0 0 0